Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma

Radiation Oncology Investigations

Volumn 7, Issue 4, 1999, Pages 218-230

  Yuan, Xuan ^a   Tabassi, Kevin ^b   Williams, Jeffery A ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Malignant glioma; Polymers; Radiotherapy; Tirapazamine

Indexed keywords

TIRAPAZAMINE;

ANIMAL EXPERIMENT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; GLIOBLASTOMA; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; TREATMENT INDICATION;

ABSORBABLE IMPLANTS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DECANOIC ACIDS; DRUG CARRIERS; DRUG IMPLANTS; GLIOMA; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; POLYESTERS; TREATMENT OUTCOME; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0032886847     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6823(1999)7:4<218::AID-ROI3>3.0.CO;2-C     Document Type: Article

References (55)

1. Grossman SA, Wharam M, Sheidler V, Kleinberg L, Zeltzman M, Yue N, Piantadosi S. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma [see comments]. J Clin Oncol 1997;15:2596-2603.
2. Halligan JB, Stelzer KJ, Rostomily RC, Spence AM, Griffin TW, Berger MS. Operation and permanent low activity 1251 brachytheraphy for recurrent high-grade astrocytomas. Int J Radiat Oncol Biol Phys 1996;35: 541-547.
3. Alexander E III, Loeffler JS. Radiosurgery for primary malignant brain tumors. Semin Surg Oncol 1998;14: 43-52.
4. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983;52:997-1007.
5. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49:333-343.
6. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5: 1725-1731.
7. Curran WJ Jr, Scott CB, Weinstein AS, Martin LA, Nelson JS, Phillips TL, Murray K, Fischbach AJ, Yakar D, Schwade JG, et al. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol 1993;11:857-862.
8. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26:239-244.
9. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-911.
10. Bashir R, Hochberg F, Oot R. Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 1988; 23:27-30.
11. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989;16:1405-1409.
12. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group [see comments]. Lancet 1995;345:1008-1012.
13. Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 1997;39:383-389.
14. Brem H. Polymers to treat brain tumors. Biomaterials 1990;11:669-701.
15. Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain. Cancer Res 1993;53:329-333.
16. Walter KA, Cahan MA, Gur A, Tyler B, Hilton J, Colvin OM, Burger PC, Domb A, Brem H. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 1994;54:2207-2212.
17. Weingart JD, Sipos EP, Brem H. The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 1995;82:635-640.
18. Judy KD, Olivi A, Buahin KG, Domb A, Epstein JI, Colvin OM, Brem H. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J Neurosurg 1995;82:481-486.
19. Siemann DW. Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys 1984;10: 1585-1594.
20. Brown J. Exploitation of bioreductive agents with vasoactive drugs. London: Taylor and Francis; 1988. Vol. 2, p 719-724.
21. Hall E. Radiobiology for the radiologist. New York: Lippincott; 1994.
22. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 1994;29: 427-431.
23. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18- fluoromisonidazole. J Nucl Med 1992;33:2133-2137.
24. Brown JM, Lemmon MJ. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation [see comments]. Int J Radiat Oncol Biol Phys 1991;20:457-461.
25. Brown JM. SR-4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. Br J Cancer 1993;67:1163-1170.
26. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986;12:1239-1242.
27. Walton MI, Workman P. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem Pharmacol 1990;39:1735-1742.
28. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990;50: 7745-7749.
29. Khan S, O'Brien PJ. Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations. Br J Cancer 1995;71:780-785.
30. Doherty N, Hancock SL, Kaye S, Coleman CN, Shulman L, Marquez C, Mariscal C, Rampling R, Senan S, Roemeling RV. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int J Radiat Oncol Biol Phys 1994;29:379-382.
31. Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R, Kris MG. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 1997;8:1269-1271.
32. Bedikian AY, Legha SS, Eton O, Buzaid AC, Papadopoulos N, Coates S, Simmons T, Neefe J, von Roemeling R. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol 1997;8:363-367.
33. Domb AJ, Langer R. Poly(anhydrides). 2. One-step polymerization using phosgene or diphosgene as coupling agents. Macromolecules 1988;21:1925-1929.
34. Riley CM, Shetty BV, Chetwyn NC, Kasper VT, Kindberg CG, Dicken CM. A stability-indicating assay and the preformulation characteristics of the radiosensitizer, 1,2,4-benzotriazin-3-amine 1,4-dioxide. J Pharm Biomed Anal 1993;11:131-138.
35. Norusis M. SPSS Advanced Statistics 6.1. Chicago: SPSS, Inc.; 1994.
36. Williams JA, Yuan X, Dillehay LE, Shastri VR, Brem H, Williams JR. Synthetic, implantable polymers for local delivery of IUdR to experimental human malignant glioma. Int J Radiat Oncol Biol Phys 1998;42: 631-639.
37. Mayer R, Dillehay LE, Shao Y, Song S, Zhang YG, Bartholomew RM, Williams JR. A new method for determining dose rate distribution from radioimmunotherapy using radiochromic media. Int J Radiat Oncol Biol Phys 1994;28:505-513.
38. McKeown SR, Friery OP, McIntyre IA, Hejmadi MV, Patterson LH, Hirst DG. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation [in process citation]. Br J Cancer 1996;74 (Suppl 27):S39-12.
39. Glantz SA. Primer of biostatistics. New York: Pergamon Press; 1992.
40. Parliament MB, Franko AJ, Allalunis-Turner MJ, Mielke BW, Santos CL, Wolokoff BG, Mercer JR. Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption. Br J Cancer 1997; 75:311-318.
41. Kim H, Fassihi R. Application of a binary polymer system in drug release rate modulation. 1. Characterization of release mechanism. J Pharm Sci 1997;86: 316-322.
42. Tamada JA, Langer R. Erosion kinetics of hydrolytically degradable polymers. Proc Natl Acad Sci USA 1993;90:552-556.
43. Tamada J, Langer R. The development of polyanhydrides for drug delivery applications. J Biomater Sci Polym Ed 1992;3:315-353.
44. Fung LK, Ewend MG, Sills A, Sipos EP, Thompson R, Watts M, Colvin OM, Brem H, Saltzman WM. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphatnide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998;58:672-684.
45. Grossman SA, Reinhard C, Colvin OM, Chasin M, Brundrett R, Tamargo RJ, Brem H. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992;76:640-647.
46. Dang W, Daviau T, Brem H. Morphological characterization of polyanhydride biodegradable implant gliadel during in vitro and in vivo erosion using scanning electron microscopy. Pharm Res 1996;13:683-691.
47. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993;53:4633-4636.
48. Kim IH, Brown JM. Reoxygenation and rehypoxiation in the SCCVII mouse tumor [see comments]. Int J Radiat Oncol Biol Phys 1994;29:493-497.
49. Brown JM, Giaccia AJ. Tumour hypoxia: the picture has changed in the 1990s. Int J Radiat Biol 1994;65: 95-102.
50. Brown JM, Lemmon MJ. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes. Radiother Oncol 1991;20:151-156.
51. Cardinale RM, Dillehay LE, Williams JA, Tabassi K, Brem H, Lee DJ. Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice. Radiat Oncol Invest 1998;6:63-70.
52. Walton MI, Workman P. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice. J Pharmacol Exp Ther 1993;265:938-947.
53. Durand RE, Olive PL. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat Oncol Invest 1997;5:213-219.
54. Cruickshank GS, Rampling R. Peri-tumoural hypoxia in human brain: peroperative measurement of the tissue oxygen tension around malignant brain tumours. Acta Neurochir 1994;(Suppl 60):375-377.
55. Lartigau E, Guichard M. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Br J Cancer 71996;3:1480-1485.